Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The optimal level of counseling and frequency of attendance for medication distribution has not been established for the primary care, office-based buprenorphine-naloxone treatment of opioid dependence. METHODS: We conducted a 24-week randomized, controlled clinical trial with 166 patients assigned to one of three treatments: standard medical management and either once-weekly or thrice-weekly medication dispensing or enhanced medical management and thrice-weekly medication dispensing. Standard medical management was brief, manual-guided, medically focused counseling; enhanced management was similar, but each session was extended. The primary outcomes were the self-reported frequency of illicit opioid use, the percentage of opioid-negative urine specimens, and the maximum number of consecutive weeks of abstinence from illicit opioids. RESULTS: The three treatments had similar efficacies with respect to the mean percentage of opioid-negative urine specimens (standard medical management and once-weekly medication dispensing, 44 percent; standard medical management and thrice-weekly medication dispensing, 40 percent; and enhanced medical management and thrice-weekly medication dispensing, 40 percent; P=0.82) and the maximum number of consecutive weeks during which patients were abstinent from illicit opioids. All three treatments were associated with significant reductions from baseline in the frequency of illicit opioid use, but there were no significant differences among the treatments. The proportion of patients remaining in the study at 24 weeks did not differ significantly among the patients receiving standard medical management and once-weekly medication dispensing (48 percent) or thrice-weekly medication dispensing (43 percent) or enhanced medical management and thrice-weekly medication dispensing (39 percent) (P=0.64). Adherence to buprenorphine-naloxone treatment varied; increased adherence was associated with improved treatment outcomes. CONCLUSIONS: Among patients receiving buprenorphine-naloxone in primary care for opioid dependence, the efficacy of brief weekly counseling and once-weekly medication dispensing did not differ significantly from that of extended weekly counseling and thrice-weekly dispensing. Strategies to improve buprenorphine-naloxone adherence are needed. (ClinicalTrials.gov number, NCT00023283 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Whereas treatment outcomes did not vary significantly by treatment condition,5 patient satisfaction did (F[2, 139] = 3.16, P = .03).”
From Patient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment (2007) · cites this paper as [5]
In the citing paper
“This paucity of research is particularly noteworthy given the increasing availability and demonstrated efficacy of office-based buprenorphine/naloxone treatment.5–7”
From Patient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment (2007) · cites this paper as [5]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The Effects of Psychosocial Services in Substance Abuse Treatment
McLellan, A. T. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500150065028 · Cited by 869
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577
Crits-Christoph, P. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.6.493 · Cited by 496
Ensuring balanced distribution of prognostic factors in treatment outcome research.
Stout, R. L., Wirtz, P. W., Carbonari, J. P., & Del Boca, F. K. (1994) · Journal of Studies on Alcohol, Supplement · doi:10.15288/jsas.1994.s12.70 · Cited by 461
Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark, H. W., Robillard, H., Banys, P., & Hall, S. M. (2000) · JAMA · doi:10.1001/jama.283.10.1303 · Cited by 415
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402
Carroll, K. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00049-6 · Cited by 386
Research works printed but not linked: 1
- Amato L, 2004, Cochrane Database Syst Rev, 4, CD005031
Cited by
D’Onofrio, G., O’Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015) · JAMA · doi:10.1001/jama.2015.3474 · Cited by 910
Self-citationStrang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., Marshall, B. D. L., Tyndall, M., & Walsh, S. L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0137-5 · Cited by 639
Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540
Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence
Uchtenhagen, A. (2009) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-17408 · Cited by 490
Maintenance Medication for Opiate Addiction: The Foundation of Recovery
Bart, G. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.694598 · Cited by 461
“96 In these individuals, transitioning from buprenorphine to methadone may allow for improved treatment outcome.”
BackgroundHser, Y., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., et al. (2014) · Addiction · doi:10.1111/add.12333 · Cited by 455
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update
(2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000633 · Cited by 412
Management of opioid use disorder in the USA: present status and future directions
Blanco, C., & Volkow, N. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33078-2 · Cited by 407
Amato, L., Minozzi, S., Davoli, M., & Vecchi, S. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004147.pub4 · Cited by 370
Woody, G. E., Poole, S. A., Subramaniam, G., Dugosh, K., Bogenschutz, M., Abbott, P., Patkar, A., Publicker, M., McCain, K., Potter, J. S., et al. (2008) · JAMA · doi:10.1001/jama.2008.574 · Cited by 361
“Any opioid use past week (self-report) 4 wk 63 (49-77) 26 (14-38) 4.”
InfluentialOral substitution treatment of injecting opioid users for prevention of HIV infection
Gowing, L., Farrell, M. F., Bornemann, R., Sullivan, L. E., & Ali, R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004145.pub4 · Cited by 296
Self-citationPrimary Care–Based Models for the Treatment of Opioid Use Disorder: A Scoping Review
Korthuis, P. T., McCarty, D., Weimer, M., Bougatsos, C., Blazina, I., Zakher, B., Grusing, S., Devine, B., & Chou, R. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2149 · Cited by 297
“OBOT Fiellin et al, 2002 (16)* Fiellin et al, 2006 (15)* Fiellin et al, 2008 (14) –”
D’Onofrio, G., Chawarski, M. C., O’Connor, P. G., Pantalon, M. V., Busch, S. H., Owens, P. H., Hawk, K., Bernstein, S. L., & Fiellin, D. A. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-3993-2 · Cited by 261
“Primary care-based buprenorphine treatment was continued for 10 weeks by physicians and nurses using established procedures, with visits ranging from weekly to twice monthly based on clinical stability.(13,14) Clinicians and study investigators providing buprenorphine treatment were blinded to research assessments.”
MethodSelf-citationLofwall, M. R., Walsh, S. L., Nunes, E. V., Bailey, G. L., Sigmon, S. C., Kampman, K. M., Frost, M., Tiberg, F., Linden, M., Sheldon, B., et al. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.1052 · Cited by 255
Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment
Haffajee, R. L., Bohnert, A. S. B., & Lagisetty, P. A. (2018) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2017.12.022 · Cited by 252
Opioid agonist treatment for pharmaceutical opioid dependent people
Nielsen, S., Larance, B., Degenhardt, L., Gowing, L., Kehler, C., & Lintzeris, N. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011117.pub2 · Cited by 249
Lofwall, M. R., & Walsh, S. L. (2014) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000045 · Cited by 248
“…controlled study showed that thrice-weekly versus once-weekly supervised buprenorphine dosing in OBOT produced only modest decreases in patient treatment satisfaction and no differences in treatment retention, opioid use, or medication adherence (Fiellin et al., 2006; Barry et al., 2007).”
BackgroundThe Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review
Carroll, K. M., & Weiss, R. D. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16070792 · Cited by 211
“2006 (5) 166 3 Noalcohol, benzodiazepine,”
BackgroundInfluentialFiellin, D. A., Schottenfeld, R. S., Cutter, C. J., Moore, B. A., Barry, D. T., & O’Connor, P. G. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.5302 · Cited by 184
Self-citationNaloxone treatment in opioid addiction: the risks and benefits
van Dorp, E. L., Yassen, A., & Dahan, A. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.2.125 · Cited by 179
Discontinuation of Buprenorphine Maintenance Therapy: Perspectives and Outcomes
Bentzley, B. S., Barth, K. S., Back, S. E., & Book, S. W. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.12.011 · Cited by 176
“…of any type has not yet been shown to improve outcomes beyond BMT alone (Amato, Minozzi, Davoli, & Vecchi, 2011; Downey, Helmus, & Schuster, 2000; Fiellin et al., 2013; 2006; Ling et al., 2013) and, if too restrictive, may form a barrier to continuing BMT enrollment (Gryczynski et al., 2013).”
Wen, H., Hockenberry, J. M., Borders, T. F., & Druss, B. G. (2017) · Medical Care · doi:10.1097/mlr.0000000000000703 · Cited by 165
Roman, P. M., Abraham, A. J., & Knudsen, H. K. (2011) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.01.032 · Cited by 165
Long‐Term Treatment with Buprenorphine/Naloxone in Primary Care: Results at 2–5 Years
Fiellin, D. A., Moore, B. A., Sullivan, L. E., Becker, W. C., Pantalon, M. V., Chawarski, M. C., Barry, D. T., O'Connor, P. G., & Schottenfeld, R. S. (2008) · The American Journal on Addictions · doi:10.1080/10550490701860971 · Cited by 162
Self-citationA Randomized Trial of Cognitive Behavioral Therapy in Primary Care-based Buprenorphine
Fiellin, D. A., Barry, D. T., Sullivan, L. E., Cutter, C. J., Moore, B. A., O'Connor, P. G., & Schottenfeld, R. S. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.07.005 · Cited by 159
Self-citationEffect of Buprenorphine Dose on Treatment Outcome
Fareed, A., Vayalapalli, S., Casarella, J., & Drexler, K. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2011.642758 · Cited by 159
Moore, B. A., Fiellin, D. A., Barry, D. T., Sullivan, L. E., Chawarski, M. C., O’Connor, P. G., & Schottenfeld, R. S. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0129-0 · Cited by 155
Self-citationPrimary care models for treating opioid use disorders: What actually works? A systematic review
Lagisetty, P., Klasa, K., Bush, C. A., Heisler, M., Chopra, V., & Bohnert, A. S. B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186315 · Cited by 169
Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.
Soeffing, J. M., Martin, L. D., Fingerhood, M. I., Jasinski, D., & Rastegar, D. (2009) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2009.05.003 · Cited by 132
Gordon, A. J., Drexler, K. P. G., Hawkins, E. J., Burden, J. L., Codell, N. K., Mhatre-Owens, A., Dungan, M. T., & Hagedorn, H. (2020) · Substance Abuse · doi:10.1080/08897077.2020.1787299 · Cited by 143
Buprenorphine/Naloxone: A Review of its Use in the Treatment of Opioid Dependence
Orman, J. S., & Keating, G. M. (2009) · Drugs · doi:10.2165/00003495-200969050-00006 · Cited by 160
Wyse, J. J. B., Gordon, A. J., Dobscha, S. K., Morasco, B. J., Tiffany, E., Drexler, K. P. G., Sandbrink, F., & Lovejoy, T. I. (2018) · Substance Abuse · doi:10.1080/08897077.2018.1452327 · Cited by 138
Lo‐Ciganic, W., Gellad, W. F., Gordon, A. J., Cochran, G., Zemaitis, M. A., Cathers, T., Kelley, D., & Donohue, J. M. (2015) · Addiction · doi:10.1111/add.13270 · Cited by 135
Integrating Buprenorphine Treatment into Office-based Practice: a Qualitative Study
Barry, D. T., Irwin, K. S., Jones, E. S., Becker, W. C., Tetrault, J. M., Sullivan, L. E., Hansen, H., O’Connor, P. G., Schottenfeld, R. S., & Fiellin, D. A. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0881-9 · Cited by 139
Self-citationFacilitators and barriers in implementing buprenorphine in the Veterans Health Administration.
Gordon, A. J., Kavanagh, G., Krumm, M., Ramgopal, R., Paidisetty, S., Aghevli, M., Goodman, F., Trafton, J., & Liberto, J. (2011) · Psychology of Addictive Behaviors · doi:10.1037/a0022776 · Cited by 129
Comparison of behavioral treatment conditions in buprenorphine maintenance
Ling, W., Hillhouse, M., Ang, A., Jenkins, J., & Fahey, J. (2013) · Addiction · doi:10.1111/add.12266 · Cited by 128
“Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.”
BackgroundInfluentialLong-term outcomes of office-based buprenorphine/naloxone maintenance therapy
Parran, T. V., Adelman, C. A., Merkin, B., Pagano, M. E., Defranco, R., Ionescu, R. A., & Mace, A. G. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.07.013 · Cited by 125
“Previous reports on low SES groups have examined outcomes in homeless patient populations (Alford et al., 2007; Fiellin et al., 2006; Stein et al., 2005).”
Home Buprenorphine/Naloxone Induction in Primary Care
Lee, J. D., Grossman, E., DiRocco, D., & Gourevitch, M. N. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0866-8 · Cited by 125
“9) Mental health disorder, lifetime 29 (39) 8 (29) 1.”
BackgroundArfken, C. L., Johanson, C., di Menza, S., & Schuster, C. R. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.05.004 · Cited by 118
“Importantly, clinical trials indicated that buprenorphine was efficacious and effective for the treatment of opioid dependence (Fiellin et al., 2006; Fudula et al., 2003; Johnson, Jaffe, & Fudala, 1992; Ling et al., 1998).”
BackgroundJohanson, C., Arfken, C. L., di Menza, S., & Schuster, C. R. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.07.019 · Cited by 114
Frost, M., Bailey, G. L., Lintzeris, N., Strang, J., Dunlop, A. J., Nunes, E. V., Jansen, J. B., Frey, L. C., Weber, B., Haber, P., et al. (2019) · Addiction · doi:10.1111/add.14636 · Cited by 133
“Other studies reported treatment retention of approximately ≤ 60% at 6 months with daily BPN [23,24].”
BackgroundSupply of buprenorphine waivered physicians: The influence of state policies
Stein, B. D., Gordon, A. J., Dick, A. W., Burns, R. M., Pacula, R. L., Farmer, C. M., LESLIE, D. L., & Sorbero, M. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.07.010 · Cited by 117
“…with opioid antagonist (naltrexone) and opioid agonist (methadone and buprenorphine) medications(Ball & Ross, 1991 ; Fiellin & O’Connor, 2002; Fiellin et al., 2006; Fudala et al., 2003; Johnson et al., 2000; Kakko, Svanborg, Kreek, & Heilig, 2003; Mattick, Kimber, Breen, & Davoli, 2008;…”
Comer, S. D., Sullivan, M. A., Vosburg, S. K., Manubay, J. M., Amass, L., Cooper, Z. D., Saccone, P. A., & Kleber, H. D. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02843.x · Cited by 117
Drug Treatment as HIV Prevention: A Research Update
Metzger, D. S., WOODY, G. E., & O’Brien, C. P. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181f9c10b · Cited by 113
“Buprenorphine, a relatively safe and effective partial agonist, offers a new treatment option for opiate-dependent individuals, particularly in the United States, because primary care providers can prescribe it from the office setting, away from the highly regulated methadone treatment system.(43,44) Recent reports on…”
BackgroundMedication-Assisted Treatment Use Among Pregnant Women With Opioid Use Disorder
Krans, E. E., Kim, J. Y., James, A. E., Kelley, D., & Jarlenski, M. P. (2019) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000003231 · Cited by 99
Schackman, B. R., Leff, J. A., Polsky, D., Moore, B. A., & Fiellin, D. A. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1962-8 · Cited by 100
“The clinical trial compared three office-based bup/nx treatment strategies (standard medical management with once- or thrice-weekly medication dispensing or enhanced medical management with thriceweekly medication dispensing) and was unable to detect a difference in outcome among the treatments.(26) We calculated the…”
MethodSelf-citationStein, B. D., Pacula, R. L., Gordon, A. J., Burns, R. M., LESLIE, D. L., Sorbero, M., Bauhoff, S., Mandell, T. W., & Dick, A. W. (2015) · Milbank Quarterly · doi:10.1111/1468-0009.12137 · Cited by 116
Sullivan, L. E., Moore, B. A., Chawarski, M. C., Pantalon, M. V., Barry, D. T., O’Connor, P. G., Schottenfeld, R. S., & Fiellin, D. A. (2007) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.08.004 · Cited by 101
Self-citationSchottenfeld, R. S., Chawarski, M. C., & Mazlan, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60954-x · Cited by 99
Self-citationPharmacological and Behavioral Treatment of Opioid Use Disorder
Sofuoglu, M., DeVito, E. E., & Carroll, K. M. (2018) · Psychiatric Research and Clinical Practice · doi:10.1176/appi.prcp.20180006 · Cited by 113
Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers
Schuman‐Olivier, Z., Albanese, M. A., Nelson, S. E., Roland, L., Puopolo, F., Klinker, L., & Shaffer, H. J. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.03.014 · Cited by 96
Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings
Taylor, J. L., Johnson, S., Cruz, R., Gray, J. R., Schiff, D. M., & Bagley, S. M. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-06904-4 · Cited by 114
Endogenous opiates and behavior: 2006
Bodnar, R. J. (2007) · Peptides · doi:10.1016/j.peptides.2007.09.002 · Cited by 104
“sessions [347].”
BackgroundMatson, S. C., Hobson, G., Abdel‐Rasoul, M., & Bonny, A. E. (2014) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000035 · Cited by 90
“Retention rates have ranged from 43% to 71% in studies lasting 6 months (O’Connor et al., 1996; Fiellin et al., 2006; Armstrong et al., 2010) and from 38% to 77% in studies lasting 18 months or more (Fiellin et al., 2008; Parran et al., 2010).”
BackgroundManhapra, A., Agbese, E., Leslie, D. L., & Rosenheck, R. A. (2018) · Psychiatric Services · doi:10.1176/appi.ps.201700363 · Cited by 86
Fiellin, D. A., Weiss, L., Botsko, M., Egan, J. E., Altice, F. L., Bazerman, L. B., Chaudhry, A. A., Cunningham, C. O., Gourevitch, M. N., Lum, P. J., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182097537 · Cited by 90
“Most patients received doses of buprenorphine/naloxone and office visits at a frequency that is consistent with prior research and federal guidelines.(15,16,20) Urine toxicology monitoring was less frequent, however, than what is recommended by existing guidelines on the use of buprenorphine/naloxone in the treatment…”
ResultSelf-citationPatient Perspectives of an Integrated Program of Medical Care and Substance Use Treatment
Drainoni, M., Farrell, C. M., Sorensen-Alawad, A., Palmisano, J. N., Chaisson, C. E., & Walley, A. Y. (2014) · AIDS Patient Care and STDs · doi:10.1089/apc.2013.0179 · Cited by 88
“A key difference between this program and more traditional integrated programs was the ability to provide buprenorphine/naloxone (BPN/NLX, also known by the brand name suboxone), an opioid agonist treatment which has been shown to be effective for improving substance use outcomes in primary care settings.(52) In this…”
Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities
McCarty, D. W., Priest, K. C., & Korthuis, P. T. (2017) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-040617-013526 · Cited by 92
“Many DATA-waivered physicians provide office-based opioid treatment in primary care settings prescribing buprenorphine, initiating the medication induction phase for patients and monitoring response with periodic visits, urine drug screening, and prescription refills with referrals for counseling and other support ser…”
BackgroundImpact of Continuing Care on Recovery From Substance Use Disorder
McKay, J. R. (2021) · Alcohol research · doi:10.35946/arcr.v41.1.01 · Cited by 111
Opioid use disorder in the United States: Insurance status and treatment access
Becker, W. C., Fiellin, D. A., Merrill, J. O., Schulman, B. A., Finkelstein, R., Olsen, Y. K., & Busch, S. H. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.11.018 · Cited by 79
Self-citationBell, J. R., Shanahan, M., Mutch, C., Rea, F., Ryan, A., Batey, R. G., Dunlop, A. J., & WINSTOCK, A. R. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01979.x · Cited by 91
Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA
Abraham, A. J., Andrews, C. M., Harris, S. J., & Friedmann, P. D. (2020) · Neurotherapeutics · doi:10.1007/s13311-019-00814-4 · Cited by 86
Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program
Gordon, A. J., Lo-Ciganic, W.-H., Cochran, G., Gellad, W. F., Cathers, T., Kelley, D., & Donohue, J. M. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000164 · Cited by 76
“…using buprenorphine (eitherbuprenorphine monotherapy or buprenorphine/naloxone pharmacotherapy) is an evidence-based, cost effective treatment for opioid use disorder (OUD) (Fudala et al., 2003; Fiellin et al., 2006; Barnett, 2009; Jones et al., 2009; Mattick et al., 2014; Volkow et al., 2014).”
BackgroundMethodWeiss, R. D., Potter, J. S., Provost, S. E., Huang, Z., Jacobs, P., Hasson, A., Lindblad, R., Connery, H. S., Prather, K., & Ling, W. (2010) · Contemporary Clinical Trials · doi:10.1016/j.cct.2010.01.003 · Cited by 76
“[27] study referenced above, the investigators found lower medication adherence and lower treatment retention with SMM than with EMM, but little between-group difference in the amount of reduction of illicit opioid use.”
BackgroundResultEstimating demand for primary care‐based treatment for substance and alcohol use disorders
Barry, C. L., Epstein, A. J., Fiellin, D. A., Fraenkel, L., & Busch, S. H. (2016) · Addiction · doi:10.1111/add.13364 · Cited by 85
Self-citationPatient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment
Barry, D. T., Moore, B. A., Pantalon, M. V., Chawarski, M. C., Sullivan, L. E., O’Connor, P. G., Schottenfeld, R. S., & Fiellin, D. A. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-006-0050-y · Cited by 74
Self-citationCo-occurring prescription opioid use problems and posttraumatic stress disorder symptom severity
Meier, A., Lambert-Harris, C. A., McGovern, M. P., Xie, H., An, M. L., & McLeman, B. M. (2014) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2014.910519 · Cited by 81
Mendelson, J., Flower, K., Pletcher, M. J., & Galloway, G. P. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0013637 · Cited by 71
“Fiellin found reductions in the frequency of opioid use with three different patterns of buprenorphine dispensing and counseling in a treatment group that included 15% to 20% prescription opioid users (Fiellin et al., 2006).”
Borodovsky, J. T., Levy, S., Fishman, M. J., & Marsch, L. A. (2018) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000388 · Cited by 72
Treatment of opioid use disorder in primary care
Buresh, M., Stern, R. S., & Rastegar, D. A. (2021) · BMJ · doi:10.1136/bmj.n784 · Cited by 80
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Sullivan, L. E., Barry, D. T., Moore, B. A., Chawarski, M. C., Tetrault, J. M., Pantalon, M. V., O’Connor, P. G., Schottenfeld, R. S., & Fiellin, D. A. (2006) · Clinical Infectious Diseases · doi:10.1086/508182 · Cited by 68
“unpublished manual) used in our previous study of primary care maintenance treatment [18].”
MethodSelf-citationThe Prescription Opioid Addiction Treatment Study: What have we learned
Weiss, R. D., & Rao, V. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.12.001 · Cited by 81
“Prior to the study we will describe below, only one study, with a modest population size, had examined the role of counseling in patients receiving office-based bup-nx, finding no benefit from more intensive counseling over standard medical management (Fiellin et al., 2006).”
MethodUse and misuse of buprenorphine in the management of opioid addiction
Cicero, T. J., Surratt, H. L., & Inciardi, J. A. (2007) · Journal of Opioid Management · doi:10.5055/jom.2007.0018 · Cited by 67
Sullivan, L. E., Moore, B. A., O’Connor, P. G., Barry, D. T., Chawarski, M. C., Schottenfeld, R. S., & Fiellin, D. A. (2009) · American Journal on Addictions · doi:10.1111/j.1521-0391.2009.00003.x · Cited by 67
Self-citationBuprenorphine prescribing practice trends and attitudes among New York providers
Kermack, A. S., Flannery, M., Tofighi, B., McNeely, J., & Lee, J. D. (2016) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2016.10.005 · Cited by 66
Oliva, E. M., Harris, A. H. S., Trafton, J. A., & Gordon, A. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.10.004 · Cited by 62
Jones, E. S., Moore, B. A., Sindelar, J. L., O’Connor, P. G., Schottenfeld, R. S., & Fiellin, D. A. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.07.013 · Cited by 66
“These data were collected between 2002 and 2005 (Fiellin et al., 2006).”
MethodResultSelf-citationBurns, R. M., Pacula, R. L., Bauhoff, S., Gordon, A. J., Hendrikson, H., LESLIE, D. L., & Stein, B. D. (2015) · Substance Abuse · doi:10.1080/08897077.2015.1080208 · Cited by 72
Evidence-Based Treatment of Young Adults With Substance Use Disorders
Hadland, S. E., Yule, A. M., Levy, S., Hallett, E., Silverstein, M., & Bagley, S. M. (2021) · PEDIATRICS · doi:10.1542/peds.2020-023523d · Cited by 72
Public sector low threshold office-based buprenorphine treatment: outcomes at year 7
Bhatraju, E. P., Grossman, E., Tofighi, B., McNeely, J., DiRocco, D., Flannery, M., Garment, A. R., Goldfeld, K. S., Gourevitch, M. N., & Lee, J. D. (2017) · Addiction Science & Clinical Practice · doi:10.1186/s13722-017-0072-2 · Cited by 68
Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study
Hill, K. P., Palastro, M. D., Gruber, S. A., Fitzmaurice, G. M., Greenfield, S. F., Lukas, S. E., & Weiss, R. D. (2017) · American Journal on Addictions · doi:10.1111/ajad.12622 · Cited by 66
Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder
Kiluk, B. D., Yip, S. W., DeVito, E. E., Carroll, K. M., & Sofuoglu, M. (2019) · Clinical Psychological Science · doi:10.1177/2167702619855659 · Cited by 66
“…treatment matching to patient characteristics, and there remains uncertainty regarding the level of adjunctive psychosocial counseling needed for added benefit (Carroll & Weiss, 2017; Day & Mitcheson, 2017; Fiellin et al., 2006; McLellan, Arndt, Metzger, Woody, & O’Brien, 1993; Weiss & Rao, 2017).”
BackgroundRice, D., Corace, K., Wolfe, D., Esmaeilisaraji, L., Michaud, A., Grima, A., Austin, B., Douma, R., Barbeau, P., Butler, C., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0244401 · Cited by 64
“…DSM or ICD Diagnosis Fiellin, 2013 American Journal of Medicine USA 141 33.7 (NR) Male: 74% European Descent: 90% Prescription and illicit NA No Fiellin, 2006 The New England Journal of Medicine USA 166 36.0 (NR) Male: 78% European Descent: 77% Prescription and illicit NA Yes Ghitza, 2008…”
BackgroundInfluentialInstilling hope into forensic treatment: the antidote to despair and desperation.
Hillbrand, M., & Young, J. L. (2008) · PubMed · Cited by 80
Griffin, M. L., Bennett, H. E., Fitzmaurice, G. M., Hill, K. P., Provost, S. E., & Weiss, R. D. (2015) · American Journal on Addictions · doi:10.1111/ajad.12188 · Cited by 75
Integration of care for HIV and opioid use disorder
Oldfield, B. J., Muñoz, N., McGovern, M. P., Funaro, M. C., Villanueva, M. S., Tetrault, J. M., & Edelman, E. J. (2018) · AIDS · doi:10.1097/qad.0000000000002125 · Cited by 71
“First, buprenorphine/naloxone was approved by the US Food and Drug Administration as the first schedule III medication for the treatment of OUD in 2002, heralding a new era for the outpatient management of OUD [44], including in PLWH[45].”
Godersky, M. E., Saxon, A. J., Merrill, J. O., Samet, J. H., Simoni, J. M., & Tsui, J. I. (2019) · Addiction Science & Clinical Practice · doi:10.1186/s13722-019-0139-3 · Cited by 67
“A study of patients treated with buprenorphine in an office-based setting that used computerized caps on medication bottles to monitor adherence reported that on average patients were adherent to their medication only 71% of the time [25].”
BackgroundAdverse childhood experiences predict opioid relapse during treatment among rural adults
Derefinko, K. J., García, F. I. S., Talley, K. M., Bursac, Z., Johnson, K., Murphy, J. G., McDevitt‐Murphy, M. E., Andrasik, F., & Sumrok, D. D. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2019.05.008 · Cited by 66
“, 2017), a key issue given high relapse rates among those in treatment (Fiellin et al., 2006).”
BackgroundMaremmani, I., & Gerra, G. (2010) · American Journal on Addictions · doi:10.1111/j.1521-0391.2010.00086.x · Cited by 68
Unobserved “Home” Induction Onto Buprenorphine
Lee, J. D., Vocci, F. J., & Fiellin, D. A. (2014) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000059 · Cited by 65
“…current US national prescribing guidelines published by the Center for Substance Abuse Treatment (CSAT) of the Substance Abuse and Mental Health Service Administration (SAMHSA) addressing buprenorphine induction describe observed induction as standard practice (CSAT, 2004; Fiellin et al., 2004).”
BackgroundSelf-citationStatistical Methodology for a SMART Design in the Development of Adaptive Treatment Strategies
Oetting, A. I., & Levy, J. A. (2011) · Causality and Psychopathology · doi:10.1093/oso/9780199754649.003.0013 · Cited by 56
“The simulated data reflect the types of scenarios found in substance-abuse clinical trials (Gandhi et al., 2003; Fiellin et al., 2006; Ling et al., 2005).”
BackgroundAmato, L., Minozzi, S., Davoli, M., Vecchi, S., Ferri, M., & Mayet, S. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004147.pub3 · Cited by 57
Lavonas, E. J., Banner, W., Bradt, P., Bucher‐Bartelson, B., Brown, K. R., Rajan, P. K., Murrelle, L., Dart, R. C., & Green, J. L. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2013.06.058 · Cited by 56
Narrative Review: Buprenorphine for Opioid-Dependent Patients in Office Practice
Sullivan, L. E., & Fiellin, D. A. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-9-200805060-00006 · Cited by 62
“Training for office staff should include general education about addiction and the rationale for medication treatment (45, 70).”
BackgroundMethodResultInfluentialSelf-citationBuprenorphine for the treatment of opioid dependence
Boothby, L. A., & Doering, P. L. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060403 · Cited by 66
“The effects of counseling and attendance frequency at an outpatient clinic for opioid abuse were studied in 166 patients during a 24-week randomized, controlled clinical trial.(31) Patients received either once- or thrice-weekly dispensing of buprenorphine–naloxone plus standard medical management (i.”
MethodSubramaniam, G. A., Warden, D., Minhajuddin, A., Fishman, M. J., Stitzer, M. L., Adinoff, B., Trivedi, M., Weiss, R., Potter, J., Poole, S. A., et al. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.07.010 · Cited by 54
Gustafson, D. H., Landucci, G., Mctavish, F. M., Kornfield, R., Johnson, R. A., Mares, M., Westergaard, R. P., Quanbeck, A., Alagöz, E., Pe‐Romashko, K., et al. (2016) · Trials · doi:10.1186/s13063-016-1726-1 · Cited by 57
Friedmann, P. D., & Schwartz, R. P. (2012) · Addiction Science & Clinical Practice · doi:10.1186/1940-0640-7-10 · Cited by 56
“than opioid agonist pharmacotherapy with standard medication management [13].”
BackgroundKorthuis, P. T., Fiellin, D. A., Fu, R. F., Lum, P. J., Altice, F. L., Sohler, N., Tozzi, M. J., Asch, S. M., Botsko, M., Fishl, M., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31820bc9a5 · Cited by 52
Self-citationOpioid agonist treatment for people who are dependent on pharmaceutical opioids
Nielsen, S., Tse, W. C., & Larance, B. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011117.pub3 · Cited by 66
Metadata
- Authors
- Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., & Schottenfeld, R. S.
- Affiliations
- Yale University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-07-27
- Volume
- 355
- Issue
- 4
- Pages
- 365-374
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1964032526
- Cited by
- 351
- References
- 30
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 17 · 2023: 14 · 2022: 13 · 2021: 28 · 2020: 18 · 2019: 24 · 2018: 22 · 2017: 19 · 2016: 11 · 2015: 19 · 2014: 18 · 2013: 18 · 2012: 15
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (K24DA000445, K23 DA15144, R01DA009803, K12 DA00167, K23DA015144, K12DA000167)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- opioid use disorder, buprenorphine/naloxone, medication-assisted treatment, counseling, primary care, medication adherence, opioid abstinence, urine drug testing, treatment retention
- MeSH terms
- Adult, Buprenorphine, Combined Modality Therapy, Counseling, Female, Humans, Male, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.